Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec;18(12):3143-95.
doi: 10.1158/1055-9965.EPI-09-0654.

Clinical trials methods for evaluation of potential reduced exposure products

Dorothy K Hatsukami  1 , Karen Hanson, Anna Briggs, Mark Parascandola, Jeanine M Genkinger, Richard O'Connor, Peter G Shields
Affiliations
Review

Clinical trials methods for evaluation of potential reduced exposure products

Dorothy K Hatsukami et al. Cancer Epidemiol Biomarkers Prev. 2009 Dec.

Abstract

Potential reduced exposure products (PREPs) to tobacco toxicants may have promise in reducing tobacco-related morbidity or mortality or may promote greater harm to individuals or the population. Critical to determining the risks or benefits from these products are valid human clinical trial PREP assessment methods. Such an assessment involves determining the effects of these products on biomarkers of exposure and effect, which serve as proxies for harm, and assessing the potential for consumer uptake and abuse of the product. This article identifies critical methodologic issues associated with PREP assessments, reviews the methods that have been used to assess PREPs, and describes the strengths and limitations of these methods. Additionally, recommendations are provided for clinical trial PREP assessment methods and future research directions in this area based on this review and on the deliberations from a National Cancer Institute sponsored Clinical Trials PREP Methods Workshop.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Three step model for PREP evaluation and marketing with assessment occurring by an independent scientific panel or regulatory agency after each step
Figure 2
Figure 2
Distinct components for the assessment of potential reduced exposure products
Figure 3
Figure 3
Venous blood concentrations of nicotine over time for various nicotine delivery systems
See this image and copyright information in PMC

References

    1. World Health Organization . The scientific basis of tobacco product regulation: a report of a WHO study group. World Health Organization; Geneva, Switzerland: 2007.
    1. Stratton K, Shetty P, Wallace R, Bondurant S, editors. Institute of Medicine. National Academy Press; Washington, DC: 2001. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. - PubMed
    1. Royal College of Physicians . Helping people who can't quit. Royal College of Physicians; London: 2007. Harm reduction in nicotine addiction.
    1. Brownawell AM, editor. The LSRO Report on Biological Effects Assessment in the Evaluation of Potential Reduced-Risk Tobacco Products. Life Sciences Research Office; Bethesda, Maryland: 2007.
    1. Hatsukami DK, Benowitz NL, Rennard SI, Oncken C, Hecht SS. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res. 2006;8:600–22. - PMC - PubMed

Publication types

MeSH terms

Substances